Literature DB >> 9390634

Regulation of the human immune response during tuberculosis.

J J Ellner1.   

Abstract

Pulmonary tuberculosis is characterized by depression of purified protein derivative-stimulated (PPD-stimulated) blastogenesis in peripheral blood mononuclear cells (PBMCs) as well as decreased production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma). Circulating T cells and monocytes (MNs) are nonspecifically activated in situ. PPD directly stimulates the primed MNs from patients with tuberculosis (TB) to overproduce a panoply of cytokines including transforming growth factor-beta (TGF-beta) and IL-10, which serve to depress PPD-stimulated blastogenesis and cytokine expression. Cross-modulation by these immunosuppressive MN products is superimposed on a primary T cell abnormality that persists for at least 12 months after the diagnosis of TB and involves apoptotic mechanisms.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9390634     DOI： 10.1016/s0022-2143(97)90123-2

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


  10 in total

1.  Reactivation of tuberculosis is associated with a shift from type 1 to type 2 cytokines.

Authors:  A D Howard; B S Zwilling
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis.

Authors:  S Bhattacharyya; R Singla; A B Dey; H K Prasad
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  The comparison of adenosine deaminase activity values with polymerase chain reaction results in patients with tuberculosis.

Authors:  O Canbolat; S Ulusdoyuran; G Ozgen; I Ceyhan; F Gümüşlü; A Akbay
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

5.  Reduced apoptosis and increased inflammatory cytokines in granulomas caused by tuberculous compared to non-tuberculous mycobacteria: role of MPT64 antigen in apoptosis and immune response.

Authors:  T Mustafa; H G Wiker; O Mørkve; L Sviland
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

6.  Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Authors:  P J Converse; A M Dannenberg; T Shigenaga; D N McMurray; S W Phalen; J L Stanford; G A Rook; T Koru-Sengul; H Abbey; J E Estep; M L Pitt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

7.  Expression of phospholipases A2 in primary human lung macrophages: role of cytosolic phospholipase A2-alpha in arachidonic acid release and platelet activating factor synthesis.

Authors:  Giorgio Giannattasio; Ying Lai; Francescopaolo Granata; Carine M Mounier; Laxman Nallan; Rob Oslund; Christina C Leslie; Gianni Marone; Gérard Lambeau; Michael H Gelb; Massimo Triggiani
Journal:  Biochim Biophys Acta       Date:  2008-12-16

8.  Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis.

Authors:  Maria Teresa Herrera; Martha Torres; Denarra Nevels; Carlos Núñez Perez-Redondo; Jerrold J Ellner; Eduardo Sada; Stephan K Schwander
Journal:  Tuberculosis (Edinb)       Date:  2008-10-09       Impact factor: 3.131

9.  Glutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjects.

Authors:  Vishwanath Venketaraman; Tatanisha Rodgers; Rafael Linares; Nancy Reilly; Shobha Swaminathan; David Hom; Ariel C Millman; Robert Wallis; Nancy D Connell
Journal:  AIDS Res Ther       Date:  2006-02-20       Impact factor: 2.250

10.  Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada.

Authors:  Mary R Reichler; Christina Hirsch; Yan Yuan; Awal Khan; Susan E Dorman; Neil Schluger; Timothy R Sterling
Journal:  BMC Infect Dis       Date:  2020-07-31       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.